Friday, December 14, 2018
Home Conference Coverage

Conference Coverage

Despite Receiving Similar Treatment as White Women, Black Women have Worse Breast Cancer Outcomes

Breast cancer is the most common cancer in women in the United States and worldwide. Furthermore, hormone-receptor–positive, axillary node–negative disease accounts for approximately half of all cases of breast cancer in the United States. Undated study results from the Trial Assigning IndividuaLized Options for TReatment or TAILORx study show that even with equivalent treatments in women with hormone receptor-positive,...

Lymph Node Surgery and Axillary Radiotherapy Yield Comparable 10-year Outcome in Breast Cancer

Results from the randomized, Phase III AMAROS clinical trial (NCT00014612),  presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018, in San Antonio, Texas, shows that patients with early-stage breast cancer who had cancer detected in a sentinel lymph node biopsy had comparable 10-year recurrence and survival rates following either axillary radiotherapy or axillary lymph node...

Circulating Tumor Cell Count may Help in Treatment Selection for Metastatic Breast Cancer

Results from the phase III STIC CTC clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, Texas, shows that  circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer. CTCs are cells that...

Study Shows Low-Dose Tamoxifen to be Safe and Effective in Reducing Recurrence + New Breast Disease

Data from the randomized, Phase III TAM-01 clinical trial, presented at during the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, shows that treatment with a low-dose of tamoxifen (5 mg per day; Nolvadex®; AstraZeneca) halved the risk of disease recurrence and new disease for women who had been treated with surgery following a...

Study Shows Accelerated Partial Breast Irradiation Not Equivalent to Whole Breast Irradiation

Data presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, shows that ipsilateral breast tumor recurrence (IBTR) rates 10 years after treatment could not reject the hypothesis that accelerated partial breast irradiation (PBI) after lumpectomy was inferior to whole breast irradiation (WBI). The data is from the NRG (National Surgical Adjuvant Breast...

Lifestyle Intervention Associated with Higher Disease-free Survival Rates in Breast Cancer

According to results of a study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, survivors of early-stage breast cancer who participated in a lifestyle intervention on healthy habits lost weight and experienced higher rates of disease-free survival if they completed the program. This study was funded, in part, by Chugai, Glaxo...

Exercise may Improve Cardiovascular Function During Adjuvant Breast Cancer Treatment

According to results of the Energy Balance and Breast Cancer Aspect (EBBA)-II trial (NCT02240836) , sponsored by the Norwegian Research Council, Norwegian Health Authority, Oslo University Hospital, St Olavs Hospital, and Active Against Cancer – Gjensidige Foundation, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018, women who underwent a supervised program of cardiovascular exercise...

Oxybutynin Improved Quality of Life for Breast Cancer Survivors

Treatment with oxybutynin chloride (Ditropan XL®; Janssen Pharmaceuticals) helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX. the study was funded by the Breast...

No Significant Improvement in Early-stage TNBC Patients Treated with Adjuvant Capecitabine

Treating patients who had early-stage triple-negative breast cancer (TNBC) with the chemotherapeutic agent capecitabine (Xeloda®; Genentech/Roche) after they completed surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation, according to data from the randomized, phase III GEICAM/CIBOMA clinical trial presented at the 2018 San Antonio Breast Cancer Symposium (SABCS), held in San Antonio,...

The Promise of CAR T-Cell Therapy

Chimeric  Antigen T-cell therapy or CAR T-cell therapy is one of the most promising types of immunotherapy.  Early results as well as experiences with approved CAR T-cell therapies have shown the potential to induce sustained remissions in patients with refractory disease. Because the majority of adult B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non–Hodgkin's lymphoma, remain,...

Related articles